Development of novel rivastigmine derivatives as selective BuChE inhibitors for the treatment of AD.

• Tác giả: Hongsong Chen, Yulu Du, Shuheng Huang, Yuting Li, Wenmin Liu, Zhengwei Liu, Zhipei Sang, Zhenhui Su, Zhenghuai Tan, Xinxin Wang, Yidan Xu, Qiyao Zhang, Weichang Zhang
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : Bioorganic chemistry , 2025
• Bộ sưu tập: NCBI
• ID: 717295

Tóm tắt

Alzheimer's disease (AD) is a prevalent neurodegenerative disorder among the elderly, and there are currently no effective treatment options available. Selective inhibition of butyrylcholinesterase (BuChE) has emerged as a promising strategy for AD therapeutics. In this study, we identified compound 6a as a lead candidate derived from the structural modification of rivastigmine. Our findings indicated that 6a acts as a potent selective BuChE inhibitor, demonstrating an IC